Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
142 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT06644768 | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | active not recruiting | Phase 1 / Phase 2 | 137 | Daiichi SankyoINDUSTRY | 5 | Jul 28, 2026 |
| clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT04995523 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC(ARTEMIDE-01) | active not recruiting | Phase 1 / Phase 2 | 212 | AstraZenecaINDUSTRY | 16 | Jul 14, 2026 | clinicaltrials |
| NCT07015697 | A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors | recruiting | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 7 | Jul 9, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04250155 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 195 | Genentech, Inc.INDUSTRY | 9 | Jul 2, 2026 | clinicaltrials |
| NCT03600883 | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | completed | Phase 1 / Phase 2 | 713 | AmgenINDUSTRY | 16 | Jun 30, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 11 | Jun 25, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 20 | GlaxoSmithKlineINDUSTRY | 8 | Jun 16, 2026 | clinicaltrials |
| NCT07648940 | Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients | completed | Phase 1 | 74 | Zodiac Produtos Farmaceuticos S.A.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT04521231 | A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | active not recruiting | Phase 1 / Phase 2 | 181 | AmgenINDUSTRY | 20 | May 28, 2026 | clinicaltrials |
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | active not recruiting | Phase 1 | 49 | AmgenINDUSTRY | 20 | May 28, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT05308732 | Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy | active not recruiting | Phase 1 | 20 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | May 1, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | active not recruiting | Phase 1 / Phase 2 | 48 | Servier Bio-Innovation LLCINDUSTRY | 15 | Apr 3, 2026 | clinicaltrials |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | active not recruiting | Phase 1 / Phase 2 | 410 | Immunocore LtdINDUSTRY | 17 | Mar 6, 2026 | clinicaltrials |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | active not recruiting | Phase 1 / Phase 2 | 438 | CelgeneINDUSTRY | 15 | Feb 19, 2026 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT04381650 | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 161 | TakedaINDUSTRY | 9 | Dec 10, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT03656718 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | completed | Phase 1 / Phase 2 | 139 | Bristol-Myers SquibbINDUSTRY | 12 | Nov 12, 2025 | clinicaltrials |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 59 | TakedaINDUSTRY | 4 | Nov 10, 2025 | clinicaltrials |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 11 | TakedaINDUSTRY | 15 | Oct 2, 2025 | clinicaltrials |
| NCT05705570 | Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies(CARTHIAE-1) | recruiting | Phase 1 | 30 | Nelson HamerschlakOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07049068 | Comparison of Nicotinamide Treatments for Actinic Keratosis | completed | Phase 1 | 74 | Federal University of Rio Grande do SulOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | completed | Phase 1 / Phase 2 | 211 | Agenus Inc.INDUSTRY | 9 | Jul 30, 2025 | clinicaltrials |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | completed | Phase 1 | 171 | AmgenINDUSTRY | 13 | Jul 20, 2025 | clinicaltrials |
| NCT04454658 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 14 | Jul 16, 2025 | clinicaltrials |
| NCT05487235 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 57 | Genentech, Inc.INDUSTRY | 6 | Jul 3, 2025 | clinicaltrials |
| NCT07032142 | Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote(ARCTURUS) | not yet recruiting | Phase 1 / Phase 2 | 66 | D'Or Institute for Research and EducationOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT05828303 | A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Turning Point Therapeutics, Inc.INDUSTRY | 6 | Apr 1, 2025 | clinicaltrials |
| NCT03397706 | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 64 | Viracta Therapeutics, Inc.INDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT05332340 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | completed | Phase 1 | 12 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma(CARTHEDRALL) | recruiting | Phase 1 / Phase 2 | 81 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04060862 | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer(IPATunity150) | terminated | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 8 | Nov 8, 2024 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials